Description
Global Vagal Nerve Stimulation (VNS) Market-Forecast till 2027
Vagal Nerve Stimulation Market Overview
The Vagal Nerve Stimulation (VNS) market is anticipated to surpass USD 1,076.83 million by 2027 with a significant CAGR of 10.30% during the forecast period. Vagus nerve stimulation includes the utilization of a gadget to invigorate the vagus nerve with electrical driving forces. An implantable vagus nerve trigger is presently FDA-endorsed to treat epilepsy and melancholy.
The outside Vagal Nerve Stimulation (VNS) gadgets depend totally on electrical signs that can be going through the skin and muscles of the neck without influencing the tissue it is going through. This method should be sufficiently exact to manage and get to explicit action of the nerve.
Development in innovation and the presentation of new outside VNS gadgets are relied upon to fuel the development of the vagal nerve trigger market.
The worldwide Vagal Nerve Stimulation (VNS) market is fundamentally determined by the expanding pervasiveness of neurological problems and rising speculation of biotechnology and drug ventures in R&D.
In any case, factors, for example, the greater expense of the vagal nerve stimulation treatment strategy are relied upon to confine the market’s development during the estimate time frame. Besides, the expanding vital consolidations and acquisitions will set out open doors for market players. However, the higher cost of vagal nerve stimulation treatment procedure is set to hamper the global market growth during the review period.
Segment Overview
The global Vagal Nerve Stimulation (VNS) market has been classified into products, applications, and end-user.
By-Products type the global market is divided into Implantable VNS Devices and External VNS Devices.
Based on Application the market is categorized into depression, epilepsy, and others.
In terms of the end-user segment, the global market is classified into hospitals, ambulatory surgical centers, and others.
Regional Analysis
The global vagal nerve stimulation (VNS) market, based on region, has been divided into North America, Europe, Asia-Pacific, and the Rest of the World.
North America is expected to command the global vagal stimulation (VNS) market with a healthy CAGR of 9.87% during the review period.
the regional market is attributed to the advanced technology, rising prevalence of neurological disorders, increasing healthcare expenditure, and supportive government support for research & development. Europe contributes the second position in the global vagal nerve stimulation market owing to the increasing government support and funding for research & development.
The Asia-Pacific vagal nerve stimulation market is expected to register a significant CAGR of 10.69% during the study period. The regional market is attributed to the existence of rapidly developing healthcare technology, a large patient population, and increased healthcare expenditure. The Rest of the World’s vagal nerve stimulation market is categorized into two major regions, namely the Middle East & Africa and Latin America.
Key Competitors
The major players of the global vagal nerve stimulation market are LivaNova, PLC (UK), ReShape Lifesciences Inc (US), ElectroCore Medical LLC (US), Boston Scientific Corporation (US), NeuroMetrix, Inc. (US), ImThera Medical, Inc. (US), Inspire Medical Systems, Inc (US), Parasym Ltd (UK), and Innovative Health Solutions, Inc. (the US).
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries.
Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.
Global Nerve Repair and Regeneration Market: Market Segments: By Product (Neurostimulation and Neuromodulation Devices, Biomaterials); By Application (Neurostimulation and Neuromodulation Surgeries, Diagnostics, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy); By End User (Hospitals, Ambulatory Surgical Centers and Clinics); and Region – Analysis of Market Size, Share & Trends for 2014 – 2019 and Forecasts to 2030
Table of Contents
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
1.1 MARKET ATTRACTIVENESS ANALYSIS
1.1.1 GLOBAL VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2019
1.1.2 GLOBAL VAGAL NERVE STIMULATION MARKET, BY APPLICATION, 2019
1.1.3 GLOBAL VAGAL NERVE STIMULATION MARKET, BY END USER
1.1.4 GLOBAL VAGAL NERVE STIMULATION MARKET, BY REGION
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 MARKET STRUCTURE
3 RESEARCH METHODOLOGY
3.1 RESEARCH PROCESS
3.2 PRIMARY RESEARCH
3.3 SECONDARY RESEARCH
3.4 MARKET SIZE ESTIMATION
3.5 TOP DOWN & BOTTOM-UP APPROACH
3.6 FORECAST MODEL
3.7 LIST OF ASSUMPTIONS& LIMITATIONS
4 MARKET DYNAMICS
4.1 INTRODUCTION
4.2 DRIVERS
4.2.1 INCREASING PREVALENCE OF NEUROLOGICAL DISORDERS
4.2.2 INCREASING INVESTMENT OF BIOTECHNOLOGY AND PHARMACEUTICAL INDUSTRIES IN R&D
4.2.3 DRIVERS IMPACT ANALYSIS
4.3 RESTRAINTS
4.3.1 HIGHER COST OF VAGAL NERVE STIMULATIO TREATMENT PROCEDURE
4.3.2 RESTRAINTS IMPACT ANALYSIS
4.4 OPPORTUNITIES
4.4.1 INCREASING STRATEGIC MERGERS AND ACQUISITIONS
4.5 IMPACT OF COVID-19 ON THE GLOBAL VAGAL NERVE STIMULATION MARKET
4.5.1 IMPACT ON SUPPLY CHAIN
4.5.2 IMPACT ON PRODUCTION
4.5.3 IMPACT ON PRICING
5 MARKET FACTOR ANALYSIS
5.1 SUPPLY/VALUE CHAIN ANALYSIS
5.1.1 R&D
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION & SALES
5.1.4 POST-SALES MONITORING
5.2 PORTER’S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 BARGAINING POWER OF BUYERS
5.2.4 THREAT OF SUBSTITUTES
5.2.5 INTENSITY OF RIVALRY
5.3 GLOBAL VNS DEVICE NEWLY IMPLANTED & RE-IMPLANTED BY VOLUME
5.4 EUROPE VNS DEVICE NEWLY IMPLANTED & RE-IMPLANTED BY VOLUME
5.5 US VNS DEVICE NEWLY IMPLANTED & RE-IMPLANTED BY VOLUME
5.6 VNS DEVICE IMPLEMENTED PATIENTS, BY COUNTRY, 2019
6 GLOBAL VAGAL NERVE STIMULATION MARKET, BY PRODUCTS
6.1 OVERVIEW
6.2 IMPLANTABLE VNS DEVICES
6.3 EXTERNAL VNS DEVICES
7 GLOBAL VAGAL NERVE STIMULATION MARKET, BY APPLICATION
7.1 OVERVIEW
7.2 DEPRESSION
7.3 EPILEPSY
7.4 OTHERS
8 GLOBAL VAGAL NERVE STIMULATION MARKET, BY END USER
8.1 OVERVIEW
8.2 HOSPITALS
8.3 AMBULATORY SURGICAL CENTERS
8.4 OTHERS
9 GLOBAL VAGAL NERVE STIMULATION MARKET, BY REGION
9.1 OVERVIEW
9.2 NORTH AMERICA
9.2.1 US
9.2.2 CANADA.
9.3 EUROPE
9.3.1 GERMANY
9.3.2 FRANCE.
9.3.3 UK
9.3.4 ITALY
9.3.5 SPAIN.
9.3.6 REST OF EUROPE.
9.4 ASIA-PACIFIC
9.4.1 CHINA
9.4.2 INDIA.
9.4.3 JAPAN.
9.4.4 AUSTRALIA.
9.4.5 SOUTH KOREA.
9.4.6 REST OF ASIA-PACIFIC.
9.5 REST OF THE WORLD
9.5.1 MIDDLE EAST
9.5.2 AFRICA.
9.5.3 LATIN AMERICA
10 COMPETITIVE LANDSCAPE
10.1 COMPETITIVE OVERVIEW
10.2 GLOBAL VAGAL NERVE STIMULATION MARKET: COMPANY SHARE ANALYSIS
10.3 COMPETITIVE BENCHMARKING
10.4 MAJOR GROWTH STRATEGY IN THE GLOBAL VAGAL NERVE STIMULATION MARKET
10.5 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN GLOBAL VAGAL NERVE STIMULATION MARKET
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
10.6.1 NEW PRODUCTS LAUNCH/SERVICE DEPLOYMENT
10.6.2 MERGER & ACQUISITION
10.6.3 COLLABORATION
10.7 MAJOR PLAYERS FINANCIAL MATRIX & MARKET RATIO
10.7.1 SALES & OPERATING INCOME
10.7.2 R&D EXPENDITURE
11 COMPANY PROFILES
11.1 LIVANOVA PLC
11.1.1 COMPANY OVERVIEW
11.1.2 FINANCIAL OVERVIEW
11.1.3 PRODUCTS OFFERED
11.1.4 KEY DEVELOPMENTS
11.1.5 SWOT ANALYSIS
11.1.6 KEY STRATEGIES
11.2 RESHAPE LIFESCIENCES, INC.
11.2.1 COMPANY OVERVIEW
11.2.2 FINANCIAL OVERVIEW
11.2.3 PRODUCTS OFFERED
11.2.4 KEY DEVELOPMENTS
11.2.5 SWOT ANALYSIS
11.2.6 KEY STRATEGIES
11.3 ELECTROCORE MEDICAL LLC
11.3.1 COMPANY OVERVIEW
11.3.2 FINANCIAL OVERVIEW
11.3.3 PRODUCTS OFFERED
11.3.4 KEY DEVELOPMENTS
11.3.5 SWOT ANALYSIS
11.3.6 KEY STRATEGIES
11.4 BOSTON SCIENTIFIC CORPORATION
11.4.1 COMPANY OVERVIEW
11.4.2 FINANCIAL OVERVIEW
11.4.3 PRODUCTS OFFERED
11.4.4 KEY DEVELOPMENTS
11.4.5 SWOT ANALYSIS
11.4.6 KEY STRATEGIES
11.5 NEUROMETRIX, INC.
11.5.1 COMPANY OVERVIEW
11.5.2 FINANCIAL OVERVIEW
11.5.3 PRODUCTS OFFERED
11.5.4 KEY DEVELOPMENTS
11.5.5 SWOT ANALYSIS
11.5.6 KEY STRATEGIES
11.6 IMTHERA MEDICAL INC.
11.6.1 COMPANY OVERVIEW
11.6.2 FINANCIAL OVERVIEW
11.6.3 PRODUCTS OFFERED
11.6.4 SWOT ANALYSIS
11.6.5 KEY STRATEGIES
11.7 INSPIRE MEDICAL SYSTEMS, INC.
11.7.1 COMPANY OVERVIEW
11.7.2 FINANCIAL OVERVIEW
11.7.3 PRODUCTS OFFERED
11.7.4 KEY DEVELOPMENTS
11.7.5 SWOT ANALYSIS
11.7.6 KEY STRATEGIES
11.8 PARASYM LTD
11.8.1 COMPANY OVERVIEW
11.8.2 FINANCIAL OVERVIEW
11.8.3 PRODUCTS OFFERED
11.8.4 KEY DEVELOPMENTS
11.8.5 SWOT ANALYSIS
11.8.6 KEY STRATEGIES
11.9 INNOVATIVE HEALTH SOLUTIONS INC.
11.9.1 COMPANY OVERVIEW
11.9.2 FINANCIAL OVERVIEW
11.9.3 PRODUCTS OFFERED
11.9.4 KEY DEVELOPMENTS
11.9.5 SWOT ANALYSIS
11.9.6 KEY STRATEGIES
12 APPENDIX
12.1 REFERENCES
12.2 RELATED REPORTS
